19:05 , Jun 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine/Metabolic

INDICATION: Diabetes Patient sample and mouse studies suggest inhibiting ANGPTL4 could help treat insulin resistance. In non-diabetic individuals, a loss-of-function mutation in ANGPTL4 was associated with low levels of fasting blood glucose and high insulin sensitivity....
23:22 , Jan 26, 2017 |  BC Innovations  |  Strategy

Deep roots

Regeneron Pharmaceuticals Inc. is starting to see the fruits of its experiment with Geisinger Health System to mine vast quantities of patient data for links between genotype and phenotype. Three years into the project, the...
14:18 , Dec 22, 2016 |  BC Innovations  |  Targets & Mechanisms

Opportunity Knocks

Despite its continued emphasis on tapping external innovation for new opportunities, industry is still leaving on the table scores of unexploited drug targets identified at universities, according to an analysis of BioCentury’s BCIQ: BioCentury Online...
07:00 , Jun 18, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Angiopoietin-like 4 (ANGPTL4)

Ophthalmic disease INDICATION: Diabetic retinopathy In vitro studies suggest inhibiting ANGPTL4 could help treat proliferative diabetic retinopathy (PDR). ANGPTL4 levels were higher in aqueous fluid from the eyes of PDR patients than in fluid from diabetic patients...
08:00 , Jan 30, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Renal disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Renal disease Renal disease Angiopoietin-like 4 (ANGPTL4); integrin aVb5 Rat studies suggest...
07:00 , Sep 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Diabetic retinopathy; diabetic macular edema (DME) Angiopoietin-like 4 (ANGPTL4) Mouse and cell culture studies suggest inhibiting...
08:00 , Feb 11, 2013 |  BioCentury  |  Emerging Company Profile

GeneCentric: Cancer sign-off

GeneCentric Diagnostics Inc. was founded to translate gene sequences into out-licensable assets for partners to market as laboratory-developed tests. The first product based on a GeneCentric assay - a test to help subtype non-small cell...
08:00 , Dec 3, 2012 |  BioCentury  |  Emerging Company Profile

Lipigon: LPL protectorate

Lipoprotein lipase has long been a desirable target to treat atherosclerosis, but direct-acting activators of the enzyme have failed. Lipigon Pharmaceuticals AB is taking a different tack, developing small molecules that protect the enzyme from...
07:00 , Mar 31, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Angiopoietin-like 4 (ANGPTL4) In vitro and mouse studies suggest that inhibiting...
07:00 , Aug 19, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Kaposi's sarcoma (KS) Angiopoietin-like 4 (ANGPTL4) In vitro and mouse studies suggest that inhibiting ANGPTL4 could...